Pradaxa Internal Bleeding Lawsuit

Background information on Power Morcellation lawsuits, settlements and litigation updates published between 2011 to 2019.

Pradaxa Lawsuit Overview

The Pradaxa litigation centered on allegations that the blood thinner dabigatran, manufactured by Boehringer Ingelheim, caused uncontrollable and often fatal bleeding in patients.

Approved in 2010 as a more convenient alternative to warfarin, Pradaxa was promoted for its ease of use and lack of routine blood monitoring. However, soon after its release, reports began to emerge of patients suffering severe internal bleeding, gastrointestinal hemorrhages, and strokes. Lawsuits claimed that the company failed to warn doctors and consumers that, unlike warfarin, Pradaxa initially had no available antidote to reverse its anticoagulant effects during medical emergencies.

As injuries and deaths mounted, thousands of lawsuits were filed nationwide accusing Boehringer Ingelheim of negligence, design defects, and failure to warn. Plaintiffs alleged that the company was aware of the drug’s risks from pre-approval studies and post-market reports but chose to market Pradaxa as a safer and simpler alternative to traditional blood thinners. The litigation also focused on internal documents suggesting that the manufacturer may have downplayed bleeding concerns to protect sales and avoid costly safety studies.

In 2014, Boehringer Ingelheim agreed to pay $650 million to settle approximately 4,000 pending claims without admitting wrongdoing. The settlement followed growing public and regulatory pressure over the drug’s safety and ultimately spurred the development of a reversal agent, Praxbind, to help manage bleeding emergencies. The Pradaxa lawsuits became one of the first major legal battles over next-generation anticoagulants, highlighting the risks of introducing new blood thinners without reliable safeguards in place.

Pradaxa Litigation Updates

November 8, 2019: Jury Awards $1.25 Million in Pradaxa Gastrointestinal Bleeding Verdict

A jury awarded $1.25 million to the family of a woman who suffered fatal gastrointestinal bleeding while taking Pradaxa. The verdict found that Boehringer Ingelheim failed to adequately warn about the anticoagulant’s risks, reigniting scrutiny years after earlier settlements resolved most claims.

May 10, 2018: Wrongful Death Verdict Returned in Pradaxa Bleeding Lawsuit

A jury sided with a plaintiff who claimed that inadequate Pradaxa warnings led to a fatal internal bleeding event. The decision came as one of the few post-settlement cases to reach trial, demonstrating continuing accountability for Boehringer Ingelheim.

November 18, 2016: Wrongful Death Lawsuit Over Pradaxa Bleeding Proceeds to Trial

A federal judge allowed a wrongful death claim to move forward, rejecting defense arguments for dismissal. The ruling underscored that new Pradaxa bleeding claims continued to emerge even years after the initial MDL had closed.

February 11, 2015: New Pradaxa Lawsuits Filed Following 2014 Settlement

Despite a $650 million global settlement reached the previous year, additional lawsuits were filed alleging that Pradaxa users continued to suffer uncontrollable bleeding. Plaintiffs claimed the drugmaker failed to make post-market label improvements.

May 29, 2014: Pradaxa Settlement Reached to Resolve Thousands of Lawsuits

Boehringer Ingelheim agreed to pay $650 million to settle about 4,000 lawsuits involving allegations that Pradaxa caused severe and sometimes fatal bleeding events. The deal resolved years of MDL proceedings over the lack of an effective reversal agent.

May 14, 2014: Pradaxa Settlement Committee of Lawyers Formed

Attorneys representing plaintiffs established a committee to coordinate settlement negotiations and distribution. The move followed months of discovery disputes and pretrial delays in the multidistrict litigation.

December 6, 2013: Pretrial Schedule Updated for Pradaxa Lawsuit MDL

The federal court overseeing Pradaxa litigation issued an amended pretrial schedule, outlining discovery completion dates and early bellwether trials. The timeline reflected the MDL’s progression toward possible global resolution.

October 22, 2013: Pradaxa Discovery Abuses Lead to Sanctions Against Boehringer

A U.S. District Judge sanctioned Boehringer Ingelheim for failing to produce critical discovery materials in good faith. The court found that the drugmaker withheld evidence concerning internal discussions of Pradaxa’s bleeding risks.

August 27, 2013: Pradaxa Trial Schedule Adjusted for Early Bellwether Cases

The court revised its initial bellwether calendar to streamline case management for the growing number of claims. The changes prioritized representative cases to gauge jury response to key liability issues.

May 29, 2013: Pradaxa Bleeding Lawsuits Continue to Mount Nationwide

Hundreds of new cases were filed in federal and state courts alleging severe bleeding complications from Pradaxa. The increase followed reports that the drug caused higher-than-expected rates of uncontrollable hemorrhages.

March 6, 2013: Internal Documents Reveal Company Knowledge of Pradaxa Risks

Previously sealed documents indicated that Boehringer Ingelheim was aware of Pradaxa’s bleeding dangers long before they were disclosed publicly. The revelation fueled additional lawsuits and public criticism of the manufacturer’s marketing practices.

February 22, 2013: Pradaxa Bellwether Lawsuits Selected for Early Trials

The MDL court finalized the selection of bellwether cases to test evidence before juries. The decision marked a key milestone in preparing for the first wave of Pradaxa trials.

December 17, 2012: Court Sanctions Boehringer Ingelheim for Bad Faith Conduct

The judge overseeing Pradaxa litigation sanctioned the manufacturer after determining it acted in bad faith by withholding or delaying production of documents. The penalties added pressure for potential settlement negotiations.

September 17, 2012: Bellwether Lawsuits Selected in Pradaxa Litigation

Several cases were chosen as bellwether trials to represent the broader group of Pradaxa lawsuits. The selections aimed to evaluate the strength of claims alleging the drug caused uncontrollable bleeding and deaths.

July 26, 2012: Protective Order Granted for Boehringer Pradaxa Depositions

The MDL court issued a protective order governing the release of sensitive discovery materials and deposition transcripts. The move was intended to balance transparency with proprietary data concerns.

June 6, 2012: Early Pradaxa Trial Dates Announced in MDL

The U.S. District Court released tentative dates for the first federal Pradaxa trials. The scheduling helped advance litigation that had quickly grown to include thousands of plaintiffs nationwide.

April 5, 2012: Class Action Claims Dismissed in Pradaxa Litigation

A federal judge dismissed proposed class action claims in the Pradaxa MDL, ruling that the cases must proceed individually due to varying injuries and circumstances. The decision allowed individual plaintiffs to continue pursuing personal injury lawsuits.

March 15, 2012: Mediator Appointed to Oversee Pradaxa Settlement Talks

A mediator was selected to coordinate ongoing negotiations aimed at resolving the Pradaxa litigation. The appointment reflected both parties’ interest in avoiding lengthy and costly trials.

January 17, 2012: Early Trial Case Selection Process Begins in Pradaxa MDL

Lawyers on both sides identified representative cases for early bellwether trials to help evaluate liability and potential damages. These selections became central to later settlement discussions.

November 22, 2011: Marketing Discovery Expands in Pradaxa Litigation

Plaintiffs were granted access to Boehringer Ingelheim’s internal marketing materials, seeking to prove the company minimized the blood thinner’s risks in advertising. The decision increased pressure on the manufacturer ahead of trial.

May 21, 2011: Pradaxa Lawsuit Trials Scheduled in Federal MDL

The federal judge overseeing the Pradaxa MDL issued a pretrial order setting dates for the first trials. The plan aimed to test key scientific evidence regarding bleeding injury claims.

May 20, 2011: Pradaxa Settlement Negotiations Ordered Before First MDL Trials

The court instructed both parties to enter mediation before proceeding to bellwether trials. The order was designed to encourage early resolution given the high number of pending claims.

May 19, 2011: Pradaxa Lawyers Appointed to MDL Leadership Roles

Attorneys representing plaintiffs were assigned leadership positions within the MDL, giving them responsibility for coordinating discovery and case strategy across all federal claims.

March 12, 2011: Pradaxa MDL Conference Scheduled to Establish Procedures

The U.S. District Court set the first conference for the consolidated Pradaxa litigation to determine procedural rules and discovery timelines.

February 7, 2011: Pradaxa MDL Formed to Consolidate Federal Lawsuits

The Judicial Panel on Multidistrict Litigation centralized Pradaxa bleeding injury lawsuits in the Southern District of Illinois. The MDL structure streamlined pretrial proceedings for the growing number of federal cases.

January 26, 2011: Judge Denies Dismissals in Pradaxa Lawsuits

A court rejected Boehringer Ingelheim’s motion to dismiss several Pradaxa cases, allowing claims of inadequate warning and design defect to move forward.

December 20, 2010: Growing Support for Centralizing Pradaxa Lawsuits

Attorneys for both plaintiffs and the manufacturer filed motions in support of consolidating Pradaxa cases in a single court to improve efficiency.

December 5, 2010: JPML Considers Consolidating Pradaxa Bleeding Lawsuits

The U.S. Judicial Panel on Multidistrict Litigation began evaluating whether Pradaxa lawsuits should be centralized, marking the first major step toward coordinated federal proceedings.

November 18, 2010: Motion Filed to Create Pradaxa MDL Over Bleeding Complaints

Plaintiffs filed a petition to consolidate all federal Pradaxa lawsuits involving uncontrolled bleeding injuries. The motion cited efficiency and consistency concerns given the rapid increase in case filings.

October 14, 2010: Pradaxa Injury Lawsuits Begin to Roll In

The first wave of Pradaxa product liability lawsuits was filed across the country, alleging that Boehringer Ingelheim failed to warn patients about the risk of fatal bleeding without a reversal agent.

Pradaxa Research and Reports

November 11, 2015: Report Claims FDA Approved Pradaxa Despite Sloppy Clinical Trial Data

A detailed investigative report alleged that the FDA approved Pradaxa even after internal reviewers raised concerns about flawed clinical trials and incomplete safety data. The findings suggested the drug’s true bleeding and mortality risks were underestimated before market release.

March 12, 2015: Study Links Pradaxa to Higher Gastrointestinal Bleeding Risks

New research indicated that Pradaxa users faced a significantly greater risk of gastrointestinal bleeding compared to patients taking warfarin. The findings reignited debate over the drug’s safety and the need for stronger post-market monitoring.

July 7, 2014: FDA Study Finds Blood Thinners Require Closer Patient Monitoring

Federal health officials released data suggesting that new-generation blood thinners like Pradaxa may need closer medical supervision despite claims of easier use than warfarin. The study highlighted ongoing safety concerns over bleeding complications.

April 23, 2014: Study Raises Questions About Pradaxa’s Clinical Data Integrity

An independent medical review questioned the accuracy of Pradaxa’s pre-approval clinical trial data, citing errors in patient tracking and incomplete reporting of adverse events. Critics said the flawed studies may have downplayed the drug’s bleeding risks.

February 12, 2014: Researchers Examine Pradaxa Bleeding Risks and Reversal Agent Efficacy

A study explored new options for reversing Pradaxa-related bleeding events using experimental antidotes. Findings showed promise but underscored that no FDA-approved reversal agent was yet available at the time.

December 3, 2013: Reports Suggest Pradaxa Manufacturer Withheld Bleeding Risk Data

Internal communications revealed Boehringer Ingelheim may have concealed information about Pradaxa’s bleeding hazards to protect sales. The disclosure intensified scrutiny over the company’s handling of post-market safety data.

October 21, 2013: FDA Evaluates Pradaxa Safety Following Bleeding Concerns

The FDA launched a comprehensive review of Pradaxa bleeding risks after rising numbers of adverse event reports. Officials examined whether patients with kidney impairment were at greater risk due to the drug’s accumulation in the body.

June 28, 2013: Study Finds Pradaxa Reversal Agent Effective in Emergency Settings

Preliminary research showed that an experimental Pradaxa antidote could reverse its anticoagulant effects within minutes. The development offered hope for doctors treating severe internal bleeding cases.

March 5, 2013: Studies Show Pradaxa May Increase Brain Bleed Risks

Two new studies found Pradaxa users were more likely to suffer intracranial hemorrhages compared to those taking other anticoagulants. The findings reinforced calls for stronger warnings and patient selection criteria.

February 21, 2013: FDA Orders Pradaxa Warning Label Update

The FDA required Boehringer Ingelheim to update Pradaxa’s label with clearer information on bleeding risks and contraindications for patients with kidney disease. The move came amid widespread concerns over patient safety.

November 8, 2012: Pradaxa Deaths Outnumber Warfarin in Bleeding Fatalities

FDA adverse event data showed more deaths linked to Pradaxa than to warfarin, contradicting early claims that the newer drug posed fewer bleeding dangers. Researchers urged regulators to reconsider its risk-benefit balance.

August 3, 2012: Study Questions Pradaxa’s Relative Safety Compared to Warfarin

An analysis of hospital data found Pradaxa users experienced higher rates of major bleeding than those treated with warfarin, challenging manufacturer claims of superior safety. The study added to calls for increased regulatory oversight.

May 22, 2012: Physicians Express Concern Over Pradaxa’s Long-Term Risks

A growing number of doctors voiced unease about Pradaxa’s safety profile, citing unpredictable bleeding events and lack of a reversal agent. Medical associations urged closer patient monitoring and more transparent data reporting.

April 17, 2012: Pradaxa Label Updated With New Warnings on Bleeding Risks

The FDA approved an updated Pradaxa label to include additional caution for patients at risk of uncontrolled bleeding. The update followed international pressure to enhance safety communications.

February 13, 2012: Pradaxa and Coumadin Top FDA’s Adverse Event Reports

An FDA analysis found Pradaxa and Coumadin accounted for the majority of serious bleeding-related adverse events nationwide. The agency began reviewing comparative risk data between the two anticoagulants.

December 15, 2011: Pradaxa Brain Hemorrhage Risk Confirmed in New Study

A published study confirmed elevated rates of intracranial hemorrhage among Pradaxa users, especially in elderly patients and those with pre-existing kidney conditions. Researchers called for additional clinical monitoring.

November 18, 2011: Canada Issues Pradaxa Warning Over Kidney-Related Bleeding Risks

Health Canada advised doctors to closely monitor kidney function in patients prescribed Pradaxa after reports linked renal impairment to excessive bleeding. The warning reflected growing global concern over the drug’s safety.

September 12, 2011: Pradaxa Internal Bleeding Reports Continue to Rise

The FDA received a surge of internal bleeding complaints involving Pradaxa, with many cases resulting in hospitalization or death. Regulators began reassessing the adequacy of existing warning labels.

July 25, 2011: Study Links Pradaxa to Higher Bleeding Risk Than Expected

Early post-market surveillance data showed that Pradaxa patients experienced major bleeding events at higher rates than seen in clinical trials. Experts questioned whether dosing recommendations needed revision.

June 30, 2011: FDA Reports Spike in Pradaxa Bleeding and Death Events

The FDA identified hundreds of deaths potentially tied to Pradaxa-related bleeding complications in its first year on the market, prompting an investigation into whether risk information was adequately communicated.

May 23, 2011: Pradaxa Linked to Elevated Bleeding Risks in Early Studies

Researchers found that Pradaxa’s anticoagulant effect was more potent than expected in certain populations, increasing the likelihood of hemorrhage. The study suggested a need for better dosing guidelines.

May 16, 2011: Pradaxa Heart Attack Study Raises Additional Safety Questions

A clinical review suggested Pradaxa users may have an elevated risk of heart attacks compared to warfarin patients. The findings conflicted with earlier claims that the drug offered superior cardiovascular protection.

May 9, 2011: Medical Experts Express Concern Over Pradaxa Safety Issues

Doctors raised alarms about growing reports of serious Pradaxa side effects, including fatal bleeding events. The warnings urged the FDA to strengthen post-approval surveillance.

April 27, 2011: Pradaxa Deaths Investigated After Adverse Event Reports Surge

The FDA launched an investigation following reports of dozens of Pradaxa-related deaths during its first year on the market. Regulators examined whether poor patient selection and monitoring contributed to fatalities.

April 12, 2011: Early Reports Link Pradaxa to Severe Bleeding Side Effects

Medical journals began publishing evidence of uncontrolled internal bleeding among Pradaxa patients. Researchers cautioned doctors to monitor kidney function to prevent accumulation of the drug in the bloodstream.

March 29, 2011: Pradaxa Linked to Dozens of Deaths During First Year of Use

Adverse event data revealed that Pradaxa was associated with multiple fatalities within its first year on the market. Regulators began evaluating whether the drug’s benefits outweighed its life-threatening risks.

February 15, 2011: Clinical Trials of Pradaxa Questioned by Researchers

Experts reviewing Pradaxa’s pre-market studies raised concerns about inconsistent dosing data and lack of transparency in reporting bleeding events. The findings called into question the validity of the drug’s approval process.

Pradaxa Reversal Agent Praxbind

May 7, 2018: Pradaxa Reversal Agent Found Highly Effective in Follow-Up Study

Researchers published new data confirming that Praxbind, the antidote for Pradaxa, effectively reversed the drug’s anticoagulant effects in emergency situations. The study demonstrated rapid clotting restoration in patients suffering from internal bleeding or requiring urgent surgery.

February 27, 2017: FDA Approves Pradaxa Antidote Praxbind for Wider Clinical Use

The FDA expanded approval for Praxbind (idarucizumab) as the official reversal agent for Pradaxa, marking a major advance in patient safety. The decision allowed hospitals nationwide to stock the antidote for immediate use during bleeding emergencies.

October 27, 2015: Pradaxa Reversal Agent Praxbind Becomes Available in U.S. Hospitals

Boehringer Ingelheim announced that Praxbind had been released to hospitals following FDA approval, providing doctors the first-ever means of reversing Pradaxa’s blood-thinning effects. The launch was hailed as a breakthrough in anticoagulant safety management.

September 3, 2015: Pradaxa Reversal Agent Demonstrates Success in Clinical Trials

A clinical trial published by the drug’s manufacturer showed Praxbind could neutralize Pradaxa’s effects within minutes in patients suffering life-threatening bleeds. The results accelerated global efforts to secure full regulatory approval.

July 17, 2015: FDA Begins Formal Review of Pradaxa Reversal Agent

Federal regulators began evaluating Boehringer Ingelheim’s application for approval of Praxbind, the first drug designed to counteract Pradaxa-related bleeding. The review followed mounting reports of severe hemorrhages among users.

May 19, 2015: Pradaxa Antidote Shows Positive Results in European Review

The European Medicines Agency issued a favorable opinion for Praxbind, noting it effectively reversed Pradaxa’s effects in both surgical and emergency bleeding scenarios. The decision paved the way for rapid approval across EU member states.

December 17, 2014: Pradaxa Antidote Progresses Through Clinical Trials

Researchers reported that clinical trial participants experienced immediate reversal of Pradaxa’s anticoagulant effect after receiving Praxbind. The findings were considered a milestone in addressing one of the drug’s most dangerous limitations.

July 28, 2014: Pradaxa Antidote Granted FDA Fast Track Status

The FDA granted expedited review for Praxbind due to urgent public health needs. The agency cited the lack of a reversal method as a key factor contributing to fatalities among Pradaxa patients who suffered major bleeding events.

February 11, 2012: Experts Develop Reversal Protocols for New-Class Blood Thinners

Medical researchers began exploring potential reversal strategies for next-generation anticoagulants like Pradaxa. The early work underscored concerns that patients had no way to quickly stop life-threatening bleeding once the drugs were active in the bloodstream.

Pradaxa Lawsuit Examples

March 15, 2012: Pradaxa Gastrointestinal Bleeding Death Lawsuit Filed

A wrongful death lawsuit was filed after a patient allegedly died from severe gastrointestinal bleeding linked to Pradaxa. The complaint accused Boehringer Ingelheim of failing to warn doctors and consumers that the blood thinner had no available reversal agent to stop internal hemorrhages once they began.

December 12, 2011: Pradaxa Lawsuits Filed Over Uncontrolled Bleeding Deaths

Multiple families filed wrongful death lawsuits alleging that Pradaxa caused fatal bleeding events shortly after the drug’s release. The complaints claimed the manufacturer rushed the medication to market without disclosing the extent of its bleeding risks or lack of an antidote.

October 28, 2011: Pradaxa Lawsuit Filed After Patient “Bled to Death”

A family filed suit after their loved one died from massive internal bleeding allegedly caused by Pradaxa. The lawsuit asserted that Boehringer Ingelheim negligently marketed the drug as a safer alternative to warfarin despite knowing of its irreversible effects.

July 18, 2011: Pradaxa Wrongful Death Lawsuit Filed Following Fatal Bleeding Event

One of the earliest Pradaxa lawsuits was filed after a patient died from internal bleeding complications. The complaint alleged that the drugmaker failed to provide adequate warnings about the dangers of uncontrolled hemorrhage, particularly in older adults and those with kidney impairment.